Mirella Calcinai, MD
Kedrion S.p.A. · Medical Director, Clinical Development · Kedrion SpA
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mirella Calcinai, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:11 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07059000 · A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)Kedrion S.p.A. · recruiting · Chronic Primary Immune Thrombocytopenia (ITP) · study director
- Ph3NCT06963216 · A Study Investigating Coagadex in the Treatment AFXD Associated With AL AmyloidosisKedrion S.p.A. · withdrawn · Acquired Factor X Deficiency · study director
- Ph3NCT01581593 · Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)Kedrion S.p.A. · completed · Primary Immunodeficiency, Agammaglobulinemia, Hypogammaglobulinemia · study director
- Ph4NCT01531803 · Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric PatientsKedrion S.p.A. · terminated · Hypovolemia · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.